<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table1" position="float"><label>Table 1.</label><caption><title>Neurological manifestations of SARS-CoV-2 infection.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Neurological manifestations</th><th valign="top">Observations</th><th valign="top">Supportive neuro-diagnostic measures</th><th valign="top">Treatment</th><th valign="top">References</th></tr></thead><tbody><tr><td valign="top">Stroke</td><td valign="top">Ischaemic stroke, deep vein thrombosis</td><td valign="top">MRI,&#160;ECG, EKG; blood test for coagulation factors, inflammatory markers</td><td valign="top">Antiplatelet, anticoagulant, tissue plasminogen activator, intravenous thrombolysis</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>, <xref ref-type="bibr" rid="bib4">Beyrouti et al., 2020</xref>, <xref ref-type="bibr" rid="bib45">Zhou et al., 2020a</xref>, <xref ref-type="bibr" rid="bib24">Li et al., 2020</xref></td></tr><tr><td valign="top">Seizure</td><td valign="top">Generalized seizures, convulsions, tonic-clonic seizures, status- epilepticus</td><td valign="top">MRI, CT scan, EEG; CSF for viral presence</td><td valign="top">Anti-epileptic medication Levetiracetam, Clonazepam and Valproate</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Duong et al., 2020</xref>; <xref ref-type="bibr" rid="bib33">Sohal and Mansur, 2020</xref>; <xref ref-type="bibr" rid="bib3">Bernard-Valnet, 2020</xref></td></tr><tr><td valign="top">Encephalopathy</td><td valign="top">Disorientation, confusion hallucinations, altered mental status, agitation, irritability, dissociated speech, lethargy</td><td valign="top">MRI, EEG; CSF for viral presence</td><td valign="top">Treatment for related problems such as seizures</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Poyiadji et al., 2020</xref>; <xref ref-type="bibr" rid="bib10">Duong et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Yin et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Helms et al., 2020</xref>,</td></tr><tr><td valign="top">Encephalitis/meningitis</td><td valign="top">Focal neurological defects, fever, headache, other neuropsychotic symptoms</td><td valign="top">MRI, EEG; CRP levels for inflammation; CSF for viral presence</td><td valign="top">Antivirals such as Acyclovir, Favipiravir, antibiotics such&#160;as Ceftriaxone, Vancomycin, and steroids</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">Bernard-Valnet, 2020</xref>; <xref ref-type="bibr" rid="bib7">Chaumont et al., 2020</xref>; <xref ref-type="bibr" rid="bib19">Hayashi et al., 2020</xref></td></tr><tr><td valign="top">Anosmia and ageusia</td><td valign="top">Reduction or loss of taste and smell, without nasal obstruction</td><td valign="top">Self diagnosis</td><td valign="top">Usually no treatment</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>; <xref ref-type="bibr" rid="bib23">Lechien, 2020</xref>; <xref ref-type="bibr" rid="bib18">Hawthorn, 2018</xref>; <xref ref-type="bibr" rid="bib13">Fotuhi et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Galougahi et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Spinato et al., 2020</xref></td></tr><tr><td valign="top">Brain haemorrhage</td><td valign="top">Intracranial blood loss, haemorrhagic rim enhancement in multiple parts of the brain</td><td valign="top">MRI, CT scan; CSF for viral presence</td><td valign="top">Intravenous immunoglobulin</td><td valign="top"><xref ref-type="bibr" rid="bib25">Mao et al., 2020</xref>, <xref ref-type="bibr" rid="bib30">Poyiadji et al., 2020</xref></td></tr><tr><td valign="top">Myalgia, partial paralysis and/or Guillain-Barr&#233; syndrome</td><td valign="top">Facial drooping, muscle weakness, diplegia/tetraplegia or hemiplegia; GBS-progressive, ascending, symmetrical flaccid limb paralysis, along with areflexia or hyporeflexia with or without cranial nerve involvement</td><td valign="top">MRI,&#160;CSF evaluation, CPK levels for muscle tissue damage, test for anti-ganglioside&#160;antibodies, nerve conduction studies for demyelinating neuropathy evaluation</td><td valign="top">Intravenous immunoglobulin, physiotherapy</td><td valign="top"><xref ref-type="bibr" rid="bib40">Wang et al., 2020b</xref>; <xref ref-type="bibr" rid="bib36">Toscano et al., 2020</xref>; <xref ref-type="bibr" rid="bib31">Sedaghat and Karimi, 2020</xref>; <xref ref-type="bibr" rid="bib28">Oxley et al., 2020</xref>; <xref ref-type="bibr" rid="bib45">Zhou et al., 2020a</xref>; <xref ref-type="bibr" rid="bib44">Zhao et al., 2020</xref>; <xref ref-type="bibr" rid="bib5">Camdessanche et al., 2020</xref></td></tr></tbody></table></table-wrap>